DiaSorin (OTCMKTS:DSRLF) Sees Large Volume Increase – Still a Buy?

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) saw unusually-high trading volume on Tuesday . 500 shares traded hands during trading, an increase of 39% from the previous session’s volume of 361 shares.The stock last traded at $80.00 and had previously closed at $81.00.

Analyst Ratings Changes

DSRLF has been the topic of several research reports. Zacks Research upgraded DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft lowered DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, June 17th. Piper Sandler assumed coverage on DiaSorin in a research note on Thursday, June 11th. They issued a “neutral” rating on the stock. BNP Paribas Exane downgraded shares of DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th. Finally, UBS Group lowered shares of DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold”.

DiaSorin Trading Up 4.1%

The business’s fifty day simple moving average is $75.01 and its 200-day simple moving average is $76.26.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.